Project Grant R42CA281356
Award Date
8/1/23
Completion Date
7/31/24
Dollars Obligated
$601K
Federal Agency
National Cancer Institute
Federal Grant Program
93.395
Assistance Type
Project Grant
Place of Performance
미국 뉴욕
Similar Awards
The National Cancer Institute has awarded a $275,627 Project Grant to Link Biosystems Inc., a self-certified small disadvantaged business and for-profit organization, to develop the ONXPANSION bioreactor workflow. This workflow aims to enable efficient expansion of patient-derived induced pluripotent stem cells into clinically relevant cell doses to support autologous cell therapy applications. The grant supports efforts to de-risk the utility of Link Biosystems' bioreactor technology for...
This $427,095 Project Grant award from the National Cancer Institute (NCI) under the Cancer Detection and Diagnosis Research program (CFDA 93.394) will support the development of a novel microfluidic droplet-based platform (MDP) technology at Northeastern University. The objective is to generate and analyze a 3D biomimetic multicellular immunogenic tumor model that can establish multiple levels of hypoxia, investigate spatiotemporal interactions between the tumor microenvironment and...
This $811,500 Cooperative Agreement award from the National Cancer Institute (CFDA 93.396 Cancer Biology Research) will fund the development of a comprehensive platform for patient-specific mechanistic tumor modeling. The key products and services to be delivered include: Merging bioinformatics software for single-cell and spatial multi-omics data analysis with an agent-based modeling framework (PhysiCell) to simulate cell movement and interactions in virtual tissue environments. This will be...
This $554,653 Project Grant award from the National Cancer Institute (CFDA 93.394 - Cancer Detection and Diagnosis Research) supports the development of RARECYTEFINDER, a label-free, genome-wide analysis method for unbiased identification and molecular profiling of rare disseminated tumor cells (DTCs) in liquid and tissue biopsies. The key products to be delivered under this 4-year project include: Advanced development and validation of RARECYTEFINDER for accurate detection and analysis of...
This $419,133 Project Grant award from the National Cancer Institute (NCI) under the Cancer Detection and Diagnosis Research program (CFDA 93.394) supports the development of the "AsciTesPredictTM" platform - a novel "ex vivo tumor biosensor" technology using single-cell analysis to evaluate cancer cell identities and therapeutic sensitivities. The key product under this 3-year award is to harden the AsciTesPredictTM technology for wider deployment in research settings to...
This National Science Foundation (NSF) Technology, Innovation, and Partnerships (CFDA 47.084) Project Grant award of $275,000 to Cerflux Inc. aims to develop a personalized cancer treatment screening platform. The project will establish guidelines for handling solid tumor biopsy samples, generate 3D bioprinted tumor models for validation, and demonstrate the platform's ability to match patients with the most effective cancer treatments before treatment begins. This innovative approach has the...
This Project Grant award, totaling $684,367.00, was provided by the National Cancer Institute (NCI) under the Cancer Treatment Research program (CFDA 93.395). The grant supports research to identify novel biomarkers that can predict response to immune checkpoint inhibitor (ICI) therapy in patients with non-small cell lung cancer (NSCLC). The research aims to: Characterize intratumoral microbiome profiles associated with ICI response using whole-metagenome sequencing. Analyze spatial immune...
This Project Grant award from the National Cancer Institute (CFDA 93.396 Cancer Biology Research) provides funding to the University of Illinois to develop novel lung adenocarcinoma models that better capture the initiation, progression, and composition of primary human tumors. The $160,330 award, with a project period of December 1, 2024 to November 30, 2026, will support two key aims: Introducing oncogenic mutations into primary human lung stem and progenitor cells to generate tumor organoid...
This $800,000 Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) supports the development of a novel biologic therapy by Creative Biotherapeutics LLC to eradicate primary and metastatic brain cancers. The research aims to target the extracellular glucose-regulated protein 78 (eGRP78), which is upregulated in drug-resistant brain tumors and enhances cancer stem cell formation, drug resistance, and immune evasion. Preclinical studies in mice have...
This $1,274,742 Project Grant awarded by the National Cancer Institute (CFDA 93.394 - Cancer Detection and Diagnosis Research) will fund the development of a microfluidic device system to rapidly isolate and expand rare circulating tumor-reactive lymphocytes (CTRLS) from the blood of ovarian cancer patients. The project aims to engineer advanced microfluidic platforms capable of non-invasively isolating these rare immune cells from patient blood samples, rather than requiring tumor tissue...